134 related articles for article (PubMed ID: 38246783)
1. [Antitumor effects of redox-responsive nanoparticles containing platinum(Ⅳ)in ovarian cancer].
Hou HY; Tang DS; Zhang YN; Wang KY; Ao M; Luo HX; Li B
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):76-85. PubMed ID: 38246783
[No Abstract] [Full Text] [Related]
2. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
[TBL] [Abstract][Full Text] [Related]
3. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
[TBL] [Abstract][Full Text] [Related]
4. Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
Jandial DD; Messer K; Farshchi-Heydari S; Pu M; Howell SB
Gynecol Oncol; 2009 Dec; 115(3):362-6. PubMed ID: 19775736
[TBL] [Abstract][Full Text] [Related]
5. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
6. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
7. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
Wang GW; Guo W; Tang XD; Peng CL; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
[TBL] [Abstract][Full Text] [Related]
8. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
[No Abstract] [Full Text] [Related]
9. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
10. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
11. Platinum Prodrug Nanoparticles with COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer.
Yu B; Wang Y; Bing T; Tang Y; Huang J; Xiao H; Liu C; Yu Y
Adv Mater; 2024 Mar; 36(11):e2310456. PubMed ID: 38092007
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
14. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
15. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
[TBL] [Abstract][Full Text] [Related]
16. Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer.
Carlier C; Laforce B; Van Malderen SJM; Gremonprez F; Tucoulou R; Villanova J; De Wever O; Vincze L; Vanhaecke F; Ceelen W
J Pharm Biomed Anal; 2016 Nov; 131():256-262. PubMed ID: 27611097
[TBL] [Abstract][Full Text] [Related]
17. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.
Zhang M; Yue H; Huang X; Wang J; Li Z; Deng X
ACS Appl Mater Interfaces; 2022 Nov; 14(43):48502-48514. PubMed ID: 36261925
[TBL] [Abstract][Full Text] [Related]
18. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin prodrug conjugated Fe
Song H; Quan F; Yu Z; Zheng M; Ma Y; Xiao H; Ding F
J Mater Chem B; 2019 Jan; 7(3):433-442. PubMed ID: 32254730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]